Annual report pursuant to Section 13 and 15(d)

Subsequent Events

v3.22.0.1
Subsequent Events
12 Months Ended
Dec. 31, 2021
Subsequent Events  
Subsequent Events

13.   Subsequent Events

In February 2022, the Company entered into an Unrestricted Grant Research Agreement with the Bateman Horne Center of Excellence, Inc., to sponsor an open-label, pilot study for the treatment of Post-Acute Sequelae of SARS-CoV-2 (“PASC”) with a combination therapy of valacyclovir and celecoxib (“IMC-2”). The Company has agreed to provide a one-time grant in the amount of $180,000 to fund the research study.